Death From Pulmonary Fibrosis: What to Expect

Death from pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), typically results from progressive respiratory failure as scarred lung tissue gradually loses the ability to transfer oxygen into the bloodstream. Without treatment, only about one in five patients survives five years from diagnosis, and even with current antifibrotic medications, the disease remains incurable.¹ What families and patients often want to understand is not just the prognosis but the practical reality of how the end unfolds, what symptoms to expect, how those symptoms can be managed, and what the final days tend to look like.

How the Disease Progresses

Pulmonary fibrosis does not follow a straight, predictable downhill path. Some people experience a slow, steady decline in lung function over years. Others remain relatively stable for months and then plummet during a sudden flare called an acute exacerbation, a rapid worsening that can be fatal on its own. A third pattern involves stepwise drops where each setback leaves the person at a new, lower baseline. Because doctors cannot reliably tell which pattern a given patient will follow, conversations about “how much time is left” are genuinely difficult and often frustrating for everyone involved.²

Antifibrotic drugs, pirfenidone and nintedanib, can slow the rate at which lung function declines. Real-world data from a Czech registry showed that pirfenidone roughly doubled the proportion of patients alive at five years compared with no antifibrotic treatment.³ A separate large study found that median transplant-free survival was about three and a half years for patients on antifibrotics versus just over two years for those not on treatment.⁴ These medications buy time, sometimes significant time, but they do not reverse existing scarring or stop the disease entirely. Lung transplantation is the only option that can dramatically change the trajectory, and most patients are not candidates for it due to age or other health conditions.

What Is Happening Inside the Lungs

In healthy lungs, the tissue between the tiny air sacs is thin and flexible, allowing oxygen to pass easily into the blood. In pulmonary fibrosis, that tissue thickens with scar tissue, becoming stiff and rigid. As the scarring accumulates, several things go wrong at once. The lungs can no longer expand fully, the exchange of oxygen and carbon dioxide becomes increasingly inefficient, and blood flow through the lungs gets disrupted.⁵

Over time, this damage frequently leads to a secondary problem: high blood pressure in the arteries of the lungs. The combination of scar tissue destroying the lung’s architecture, blood vessels being remodeled, and low oxygen causing vessels to constrict creates a condition that further reduces exercise capacity, worsens quality of life, and shortens survival.⁶ This is why people with advanced pulmonary fibrosis can feel breathless even at rest: the problem is not just that the lungs are stiff, but that the blood flowing through them is no longer picking up enough oxygen to meet the body’s needs.

The Symptom Burden in Advanced Disease

Breathlessness is the hallmark symptom and usually the one that dominates the final stages. Early in the disease, it may only appear with vigorous activity. As fibrosis advances, the threshold drops steadily: walking across a room, getting dressed, or even talking becomes exhausting. In the final weeks, breathlessness can be present even while sitting still, and it frequently triggers intense anxiety. The sensation is often described by patients as suffocating or drowning, which makes it psychologically as well as physically distressing.

Cough is another relentless symptom. In qualitative studies, caregivers described cough as one of the most disruptive features of the illness, affecting not only the patient but everyone around them. Caregivers of deceased patients reported the greatest burden, with spouses describing being kept awake night after night by uncontrollable coughing fits.⁷ The cough in IPF is dry, persistent, and often resistant to standard cough suppressants, which adds to the frustration.

Beyond breathlessness and cough, patients in the advanced phase commonly experience fatigue that goes well beyond ordinary tiredness, weight loss as the effort of breathing burns calories the body cannot spare, and disrupted sleep. Depression and anxiety are common in people with IPF, fueled in part by the oxygen deprivation itself and in part by the awareness that the disease is progressive and incurable.⁸ These psychological symptoms are not a separate problem layered on top of the physical illness; they are part of it.

Managing Symptoms Near the End of Life

The good news, if it can be called that, is that the worst symptoms of advanced pulmonary fibrosis can be treated, and treated more aggressively than many families realize. Opioids, particularly morphine, are the cornerstone of managing severe breathlessness. This often surprises or alarms families who associate morphine with hastening death, but the evidence suggests otherwise. A large national study of patients with interstitial lung disease found that neither low-dose nor high-dose opioids were associated with increased mortality.⁹ In other words, morphine used to ease breathing does not appear to shorten life.

Oral morphine in particular has shown benefit for breathlessness in IPF. A review of the available studies found that five out of seven trials investigating oral or injected morphine detected improvements in either breathlessness or exercise capacity, and no severe side effects like respiratory depression were reported.¹⁰ Constipation was the most commonly noted side effect. Inhaled morphine, by contrast, did not seem to help with breathlessness in the studies reviewed. Low-dose morphine has also been studied for the stubborn cough that plagues IPF patients, with a randomized trial investigating whether it could reduce cough severity.¹¹

Supplemental oxygen is standard for patients whose blood oxygen levels have dropped. It helps with exertion and can ease the sensation of breathlessness, though it does not eliminate it entirely. Most patients with end-stage disease are on continuous oxygen. Non-invasive ventilation, essentially a mask that pushes air into the lungs, is sometimes used in the final stages. About a third of patients in one study received it during their last week of life, but its benefit in end-stage IPF is unproven, and it can actually increase suffering by preventing patients from speaking, eating, or being physically close to their families.¹² For this reason, the decision to use it should weigh comfort against the burden it imposes.

What the Final Days Tend to Look Like

In the final days, breathlessness typically intensifies. The person may become increasingly drowsy, partly from the disease itself and partly from the medications used to keep them comfortable. Appetite disappears. Confusion can set in as oxygen levels fall. The dying process in pulmonary fibrosis can be turbulent compared with some other terminal illnesses: a study comparing end-of-life care in patients with terminal interstitial pneumonia versus terminal lung cancer found that the interstitial pneumonia group required significantly more medication for relief of breathlessness. Half of the interstitial pneumonia patients received continuous morphine infusions, compared with about 38% of lung cancer patients. Even with morphine, breathlessness sometimes worsened again after an initial improvement, requiring the addition of a sedative to achieve relief.¹³

That finding is worth sitting with. Families are sometimes told that all terminal illnesses end in a similar, peaceful fading away. In pulmonary fibrosis, the final hours can require more active medical management than many people expect. Palliative care teams experienced with this disease understand this and can escalate medications as needed, but the process is smoother when everyone involved, the patient, the family, and the medical team, has discussed in advance what aggressive comfort care might look like.

Death itself usually comes from respiratory failure. The lungs simply can no longer deliver enough oxygen to sustain organ function. In some cases, the immediate cause is an acute exacerbation, a sudden dramatic worsening of the fibrosis. In others, complications like infections, blood clots, or heart strain from the lung disease contribute to the final event.¹⁴ But the underlying driver is almost always the progressive destruction of the lungs.

Where People With IPF Die

Despite the fact that IPF is a terminal illness, a surprising number of patients die in the hospital rather than at home or in hospice. In one study of patients with IPF, more than half, about 57%, died in the hospital, and roughly a third of all deaths occurred in the intensive care unit.¹⁵ Referral to palliative care in that same study was uncommon and tended to happen late in the disease course.

This pattern reflects several problems. The unpredictable trajectory of IPF means that patients and families often hold out hope for stability, making it hard to shift from curative-minded care to comfort-focused care. When acute exacerbations hit, the instinct is to rush to the emergency room, and once a patient is in the hospital and on a ventilator, the momentum of intensive care can be difficult to redirect. Many people with IPF never have a clear conversation about whether they would want to be intubated or whether they would prefer comfort-focused care if their lungs fail suddenly. An international panel of experts developed a set of criteria for when palliative care referral should happen in IPF, identifying 17 major triggers that include things like increasing oxygen needs, frequent hospital admissions, and severe symptom distress.¹⁶ The existence of these criteria signals that the field recognizes palliative care is being brought in too late for many patients.

Why Conversations About Dying Are So Difficult in This Disease

Pulmonary fibrosis creates a particularly difficult communication environment. Unlike some cancers where staging systems give a rough timetable, IPF’s variable course makes it genuinely hard for doctors to predict how much time a person has left. Physicians in one survey identified difficulty predicting prognosis as a significant barrier to providing palliative care, along with mismatched expectations between patients, families, and the medical team about what treatment can accomplish.¹⁷

The variable course of IPF complicates these conversations but should not prevent them from happening.² Patients deserve to know what the range of possibilities looks like, even if their doctor cannot pinpoint a date. What many families report in retrospect is that they wish someone had told them earlier what the end might look like, not to scare them, but so they could prepare. Advance care planning, deciding ahead of time what kinds of interventions the patient does and does not want, is especially important for a disease where sudden crises are a real possibility. If those wishes are not documented before an acute exacerbation strikes, the default in a hospital setting is aggressive intervention, which may not align with what the patient would have chosen.

The Toll on Caregivers and Families

Pulmonary fibrosis is not just a patient disease; it reshapes the lives of everyone around the patient. Caregivers, usually spouses, carry a weight that is easy to underestimate from the outside. The relentless cough disrupts sleep for both patient and partner. The progressive breathlessness means the caregiver takes over more and more of daily tasks, from household chores to personal care. The psychological strain is compounded by the knowledge that the disease will not get better.⁷

Bereavement after a pulmonary fibrosis death carries its own risks. A qualitative study of surviving spouses found that the nature of the illness itself, the prolonged watching of a partner slowly suffocate, the lack of adequate palliative support, and the absence of advance care planning could all contribute to prolonged, complicated grief after death.¹⁸ Some spouses described feeling traumatized by the final days, particularly when the death involved visible distress from breathlessness that they felt helpless to relieve. Early engagement with palliative care, well before the final crisis, has the potential to mitigate some of this suffering. When families have a relationship with a palliative care team, when the medications and the plan are already in place, the final phase is less chaotic and less frightening for everyone.

What Families Can Do to Prepare

Preparation is not about giving up hope. It is about making sure that when the disease reaches its final phase, the focus is entirely on the patient’s comfort and the family’s ability to be present rather than on frantic decision-making in a hospital corridor. There are concrete steps that help.

Advance directives: A written document spelling out the patient’s wishes regarding intubation, mechanical ventilation, CPR, and hospitalization gives the family and the medical team a clear guide when crisis hits. Without it, the defaults in emergency medicine tend toward aggressive intervention.
Early palliative care referral: Palliative care is not the same as hospice. It can run alongside disease-directed treatment for months or years, focusing on symptom relief, psychological support, and planning. Waiting until the final weeks means missing the window where it can do the most good.
Hospice enrollment: When the trajectory is clearly downward, enrolling in hospice ensures 24-hour access to medications, nursing support, and a team experienced with managing respiratory distress at home. Patients who die at home with hospice support tend to have a less distressing final experience than those who die in the ICU.
Caregiver support: The person providing care needs their own support system, whether that is a support group for pulmonary fibrosis caregivers, respite care, counseling, or simply honest conversations with the medical team about what to expect and when to call for help.

The gap between what is available and what most IPF patients actually receive at end of life remains wide. Physicians acknowledge the barriers, from prognostic uncertainty to poor communication to families who are not ready to hear the word “dying.” But the evidence increasingly points in one direction: earlier, more open conversations about the end of life, paired with proactive symptom management, lead to less suffering for patients and less traumatic grief for the people who love them.

Pulmonary Hypertension as a Complication in Late-Stage Disease

One complication that families may hear about as the disease progresses is pulmonary hypertension, meaning high blood pressure specifically in the blood vessels of the lungs. This is common in IPF and reflects the combined damage from scarring, changes in blood vessel structure, and the body’s response to chronically low oxygen.⁶ When it develops, it worsens exercise capacity and shortens survival beyond what the fibrosis alone would cause.¹⁹

For the patient, pulmonary hypertension mainly means more breathlessness, more fatigue, and sometimes swelling in the legs and ankles as the right side of the heart struggles to pump blood through stiffened lung vessels. Treatment options specifically for this complication in IPF remain limited, though research is active. From a practical standpoint, the development of pulmonary hypertension is a signal that the disease has entered a more advanced phase, and it can be a reasonable trigger for revisiting goals of care and palliative care involvement. Families who hear this diagnosis should understand it as a marker of disease progression, not a separate illness that requires a separate treatment plan.